Iclusig 15 mg film-coated tablets clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
This study looks at people with a type of blood cancer called CML who are doing well on a drug called Iclusig. It aims to see if they can safely stop Iclusig after taking it again, and how long they stay well without treatment.
For: Chronic myelogenous leukemiaSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia
This study looks at whether a medicine called Iclusig (ponatinib) can help people with a type of blood cancer called chronic myeloid leukaemia (CML) reach a point where no disease can be found, possibly leading to stopping treatment. It will check how well it works and if it's safe.
For: chronic myeloid leukemia in chronic phaseGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
This study is looking at a medicine called Iclusig (also known as ponatinib) for people in the UK with a type of blood cancer called chronic myeloid leukaemia (CML) that hasn't responded to previous treatments. It aims to find the best dose and understand how well it works and if it's safe.
For: Chronic Phase Chronic Myeloid LeukemiaPoland · France